发明授权
- 专利标题： Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
- 专利标题（中）： 丙泊酚或其药学上可接受的盐的延长释放活性成分的口服剂型
-
申请号： US10492270申请日： 2002-10-08
-
公开(公告)号： US07943176B2公开(公告)日： 2011-05-17
- 发明人: Thomas Gramatte , Peter Gruber , Michael Heschel , Dirk Pamperin , Jan Ploen , Steffen Scheithauser , Wolfgang Wehner , Peter Guldner
- 申请人： Thomas Gramatte , Peter Gruber , Michael Heschel , Dirk Pamperin , Jan Ploen , Steffen Scheithauser , Wolfgang Wehner , Peter Guldner
- 申请人地址： DE Dresden
- 专利权人： Apogepha Arzneimittel GmbH
- 当前专利权人： Apogepha Arzneimittel GmbH
- 当前专利权人地址： DE Dresden
- 代理机构： Vidas, Arrett & Steinkraus
- 优先权： DE10149674 20011009
- 国际申请： PCT/EP02/11253 WO 20021008
- 国际公布： WO03/030869 WO 20030417
- 主分类号： A61K9/14
- IPC分类号： A61K9/14
摘要：
By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.
公开/授权文献
信息查询
